Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Tariffs aren’t just a potential problem for civilian cars. The semi-truck industry could be rocked as well. Mack and Volvo is one of the largest American manufacturers and has decided to cut workers ...

Merge sort is entirely different than the sorting algorithms we’ve seen so far, and it represents an important class of algorithms—divide-and-conquer algorithms. Divide-and-conquer algorithms work by ...

Abstract: Sorting is a classic algorithm that is fundamental building block of many algorithms. Many algorithms requiring high speed data processing nowadays are hardware accelerated using ...

Utah-based Recursion, a clinical-stage biotech company specialising in drug discovery, has entered into a definitive agreement to merge with Oxford-based Exscientia, a clinical-stage drug design and ...

On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Armed with a combined $850 million in cash, the companies said Thursday the resulting biotech will have a pipeline that could deliver 10 clinical readouts over the next 18 months. The AI-enabled ...